Organic Vaccines Plc - Agreements with National Institutes of Health and National Cancer Institute

PARIS, November 17, 2014 /PRNewswire/ --

MERS-CoV or Middle-East Respiratory Syndrome Coronavirus   is responsible for a viral respiratory illness first reported in Saudi Arabia in 2012.  

Most people confirmed to have MERS-CoV infection developed severe acute respiratory illness. About 43% of infected people in Saudi Arabia have died (333 /780 as of Oct 29th 2014 - source CIDRAP. Globally 887 cases as of Oct 16th 2014 - source World Health Organization).

To view the Multimedia News Release, please click:

http://www.multivu.com/players/English/72762588-organic-vaccines-MERS-CoV/

Organic-Vaccines is completing necessary documentation to file an authorization for compassionate use of its Monoclonal Antibodies from the WHO. The objective is to be able to combat the recurrent mortality and be prepared for a potential outbreak in springtime. Camels give birth in spring and are suspected to be the virus reservoir. A similar stopgap action in Queensland, Australia, with similar antibodies was applied successfully on humans against Nipah and Hendra viruses without any side effects. Queensland Ministry of Health has demonstrated an efficient strategy for emergency prior to develop a vaccine to be available later. Organic-Vaccines is counting on full cooperation from Jeddah's Control and Command center and from the Saudi MOH to meet deadlines and fasten its process for being able to protect first responders and avoid disorganization of the Health System in case of emergence of a MERS CoV outbreak.

Organic-Vaccines Scientific Advisory Board: 

• Prof Bruce Beutler, MD, Chairman of the Board

Nobel Prize recipient in 2011, with Jules Hoffmann, for their discoveries on activation of innate immunity, UT Southwestern Medical Center, Dallas. Regental Professor and Director of the Center for Genetics of Host Defense  

• Prof Dominique Charron, MD, PhD, Co-Chairman  

Hôpital Saint-Louis in Paris, France. Professor of Medicine, Immunology at the University of Paris

• Prof Michel Sadelain, MD, PhD

Sloan-Kettering Institute, Head of the Gene, Transfer and Expression Laboratory

• Prof Janko Nikolich-Zugich, MD, PhD

Director of Vaccine and Gene Therapy Institute. Professor and Chairman, Dept. of Immunobiology

Co-Director, Arizona Center on Aging, University of Arizona

• Prof Astrid Vabret, MD, PhD University Hospital of Caen, France. Head of the department of

Medical Virology

• Prof Marc Weksler, MD, Weill Medical College of Cornell University in New York.

Organic Vaccines  is a life sciences company at clinical stage of development.

Organic Vaccines is dedicated to delivering personalized therapies utilizing one's own cells. Led by a world-renowned Scientific Advisory Board, including Prof. Bruce Beutler-2011 Nobel Prize Laureate - and a seasoned executive team, Organic Vaccines is introducing new vaccine technology that addresses the pain points of an underserved vaccine market. Based on an AAPC (Artificial Antigen Presenting Cell) technology and innovative molecular adjuvant from the Beutler Lab, initial clinical trials on Flu and adult HPV will open the way to the development of preventive as well as therapeutic children vaccines, including HPV. Organic-Vaccines therapeutic capabilities in synergy with monoclonal antibodies developed thanks to a collaborative agreement with the US NIH will allow Organic-Vaccines to propose a rapid answer to pandemics threats such as MERS-Cov.

Organic Vaccines is represented in KSA by Tharaa Global Holding.

http://www.organic-vaccines.com

Video: 
     http://www.multivu.com/players/English/72762588-organic-vaccines-MERS-CoV/

SOURCE Organic Vaccines